BIA
KYMR icon

Bell Investment Advisors’s Kymera Therapeutics KYMR Stock Holding History

Bell Investment Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$467 – 1908
2025
Q4 		$467 Buy
+6
New +$405 ﹤0.01% 1767
2023
Q3 		– Sell
-21
Closed -$483 – 1966
2023
Q2 		$483 Hold
21
– – ﹤0.01% 1868
2023
Q1 		$623 Hold
21
– – ﹤0.01% 1727
2022
Q4 		$524 Hold
21
– – ﹤0.01% 1802
2022
Q3 		$0 Buy
+21
New +$553 ﹤0.01% 1846

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bell Investment Advisors's KYMR Position: Q1 2026 in Review

Bell Investment Advisors sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 6 shares — an estimated $467 sold.

Bell Investment Advisors first reported a position in KYMR in Q3 2022 and held it in 5 quarters. The position peaked at $623 in Q1 2023. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Bell Investment Advisors reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bell Investment Advisors sold 6 Kymera Therapeutics shares in Q1 2026, an estimated $467.
  • Bell Investment Advisors first reported a position in Kymera Therapeutics in Q3 2022 and held it in 5 quarters.
  • Bell Investment Advisors's Kymera Therapeutics position peaked at $623 in Q1 2023.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Bell Investment Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.